Skip to main content
Download PDF

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Journal of Hematology & Oncology volume 15, Article number: 159 (2022) Cite this article

A Correction to this article was published on 20 February 2023

The Original Article was published on 18 August 2022

This article has been updated

Correction to: Journal of Hematology & Oncology (2022) 15:113 https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-022-01334-z


The original article [1] contained three erroneous citations and other minor typesetting errors in the text which have since been amended.

Change history

Reference

  1. Jiang, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15:113. https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-022-01334-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology, No. 11 South Street of Xizhimen, Xicheng District, Beijing, 100044, China

    Qian Jiang, Zongru Li, Yazhen Qin & Xiaojun Huang

  2. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China

    Weiming Li & Yu Hu

  3. Department of Hematology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou N Ave, Baiyun, Guangzhou, 510515, Guangdong Province, China

    Na Xu & Xiaoli Liu

  4. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China

    Bingcheng Liu

  5. Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450008, Henan, China

    Yanli Zhang & Yongping Song

  6. Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China

    Li Meng

  7. Department of Hematology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Wuhou District, Chengdu, 610000, Sichuan, China

    Huanling Zhu

  8. Division of Hematology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, 3002 Sungang W Rd, Futian District, Shenzhen, 518000, Guangdong Province, China

    Xin Du

  9. National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

    Suning Chen

  10. State Key Laboratory of Oncology in South China, Department of Hematologic Oncology, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, Guangdong Province, China

    Yang Liang

  11. Guangzhou Healthquest Pharma Co. Ltd., Room F314, GIBI, No. 3 Lanyue Road, Guangzhou, 510663, China

    Lichuang Men, Zi Chen, Qian Niu, Hengbang Wang & Yifan Zhai

  12. Ascentage Pharma Group Inc, 800 King Farm Blvd Suite 300, Rockville, MD, 20850, USA

    Ming Lu & Yifan Zhai

  13. Ascentage Pharma (Suzhou) Co., Ltd, 218 Xinghu St, Bldg B7, 7Th Floor, Suzhou Industrial Park, Suzhou, 215000, Jiangsu, China

    Dajun Yang

  14. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou, 510060, Guangdong Province, China

    Dajun Yang

  15. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 South Street of Xizhimen, Xicheng District, Beijing, 100044, China

    Xiaojun Huang

  16. Peking-Tsinghua Center for Life Sciences, No. 11 South Street of Xizhimen, Xicheng District, Beijing, 100044, China

    Xiaojun Huang

  17. Academy for Advanced Interdisciplinary Studies, Peking University, No. 11 South Street of Xizhimen, Xicheng District, Beijing, 100044, China

    Xiaojun Huang

Authors
  1. Qian Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zongru Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yazhen Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weiming Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Na Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bingcheng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yanli Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Li Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Huanling Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xin Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Suning Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yang Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yu Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Xiaoli Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yongping Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Lichuang Men
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Zi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Qian Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Hengbang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Ming Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Dajun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Yifan Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Xiaojun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaojun Huang.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, Q., Li, Z., Qin, Y. et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol 15, 159 (2022). https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-022-01369-2

Download citation

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s13045-022-01369-2

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us